Systematic Review and Meta-analysis: Pharmacogenetics of Anti-TNF Treatment Response in Rheumatoid Arthritis

Overview

Journal Pharmacogenomics J

Specialties Genetics
Molecular Biology
Pharmacology

Date 2017 Jun 14

PMID 28607508

Citations 51

Authors

S Bek

A B Bojesen

J V Nielsen

J Sode

S Bank

U Vogel

V Andersen

Affiliations

Soon will be listed here.

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.

Citing Articles

A Machine Learning Approach for Prediction of CDAI Remission with TNF Inhibitors: A Concept of Precision Medicine from the FIRST Registry.

Sonomoto K, Fujino Y, Tanaka H, Nagayasu A, Nakayamada S, Tanaka Y Rheumatol Ther. 2024; 11(3):709-736.

PMID: 38637465 PMC: 11111643. DOI: 10.1007/s40744-024-00668-z.

Novel DNA methylome biomarkers associated with adalimumab response in rheumatoid arthritis patients.

Hageman I, Mol F, Atiqi S, Joustra V, Sengul H, Henneman P Front Immunol. 2024; 14:1303231.

PMID: 38187379 PMC: 10771853. DOI: 10.3389/fimmu.2023.1303231.

The Effects of Periodontal Treatment on Rheumatoid Arthritis and of Anti-Rheumatic Drugs on Periodontitis: A Systematic Review.

Inchingolo F, Inchingolo A, Avantario P, Settanni V, Fatone M, Piras F Int J Mol Sci. 2023; 24(24).

PMID: 38139057 PMC: 10743440. DOI: 10.3390/ijms242417228.

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis.

Sainz L, Riera P, Moya P, Bernal S, Casademont J, Diaz-Torne C Arthritis Res Ther. 2023; 25(1):226.

PMID: 38001504 PMC: 10668502. DOI: 10.1186/s13075-023-03209-1.

Association between Proinflammatory Cytokines and Anxiety and Depression Symptoms in Rheumatoid Arthritis Patients: A Cross-sectional Study.

Parlindungan F, Hidayat R, Ariane A, Shatri H Clin Pract Epidemiol Ment Health. 2023; 19:e174501792304261.

PMID: 37916198 PMC: 10351345. DOI: 10.2174/17450179-v19-e230510-2022-34.

References

Potter C, Cordell H, Barton A, Daly A, Hyrich K, Mann D . Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis. 2010; 69(7):1315-20. DOI: 10.1136/ard.2009.117309. View

Hetland M, Christensen I, Tarp U, Dreyer L, Hansen A, Hansen I . Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide.... Arthritis Rheum. 2009; 62(1):22-32. DOI: 10.1002/art.27227. View

Fransen J, Van Riel P . The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005; 23(5 Suppl 39):S93-9. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Smith S, Plant D, Lee X, Massey J, Hyrich K, Morgan A . Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. Pharmacogenomics. 2016; 17(7):715-20. PMC: 4996314. DOI: 10.2217/pgs.16.16. View

Bek S, Nielsen J, Bojesen A, Franke A, Bank S, Vogel U . Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016; 44(6):554-67. PMC: 5113857. DOI: 10.1111/apt.13736. View

Marquez A, Ferreiro-Iglesias A, Davila-Fajardo C, Montes A, Pascual-Salcedo D, Perez-Pampin E . Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: a genome-wide association study replication and meta-analysis. Arthritis Res Ther. 2014; 16(2):R66. PMC: 4060376. DOI: 10.1186/ar4504. View

Lopez-Escamez J, Saenz-Lopez P, Gazquez I, Moreno A, Gonzalez-Oller C, Soto-Varela A . Polymorphisms of CD16A and CD32 Fcγ receptors and circulating immune complexes in Ménière's disease: a case-control study. BMC Med Genet. 2011; 12:2. PMC: 3022798. DOI: 10.1186/1471-2350-12-2. View

Iwaszko M, Swierkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K . Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy. Clin Exp Immunol. 2015; 182(3):270-7. PMC: 4636889. DOI: 10.1111/cei.12696. View

10.

Plant D, Prajapati R, Hyrich K, Morgan A, Wilson A, Isaacs J . Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2011; 64(3):665-70. PMC: 3427899. DOI: 10.1002/art.33381. View

11.

Sode J, Vogel U, Bank S, Andersen P, Hetland M, Locht H . Genetic Variations in Pattern Recognition Receptor Loci Are Associated with Anti-TNF Response in Patients with Rheumatoid Arthritis. PLoS One. 2015; 10(10):e0139781. PMC: 4595012. DOI: 10.1371/journal.pone.0139781. View

12.

Bank S, Andersen P, Burisch J, Pedersen N, Roug S, Galsgaard J . Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics J. 2014; 14(6):526-34. DOI: 10.1038/tpj.2014.19. View

13.

Swierkot J, Bogunia-Kubik K, Nowak B, Bialowas K, Korman L, Gebura K . Analysis of associations between polymorphisms within genes coding for tumour necrosis factor (TNF)-alpha and TNF receptors and responsiveness to TNF-alpha blockers in patients with rheumatoid arthritis. Joint Bone Spine. 2014; 82(2):94-9. DOI: 10.1016/j.jbspin.2014.08.006. View

14.

van der Pouw Kraan T, van Gaalen F, Kasperkovitz P, Verbeet N, Smeets T, Kraan M . Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum. 2003; 48(8):2132-45. DOI: 10.1002/art.11096. View

15.

Coulthard L, Taylor J, Eyre S, Robinson J, Wilson A, Isaacs J . Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann Rheum Dis. 2010; 70(1):98-103. DOI: 10.1136/ard.2010.133249. View

16.

Bowes J, Potter C, Gibbons L, Hyrich K, Plant D, Morgan A . Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet Genomics. 2009; 19(4):319-23. DOI: 10.1097/FPC.0b013e328328d51f. View

17.

Maxwell J, Potter C, Hyrich K, Barton A, Worthington J, Isaacs J . Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet. 2008; 17(22):3532-8. DOI: 10.1093/hmg/ddn245. View

18.

Toonen E, Coenen M, Kievit W, Fransen J, Eijsbouts A, Scheffer H . The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. Ann Rheum Dis. 2008; 67(8):1174-7. DOI: 10.1136/ard.2008.088138. View

19.

Tarnowski M, Paradowska-Gorycka A, Dabrowska-Zamojcin E, Czerewaty M, Sluczanowska-Glabowska S, Pawlik A . The effect of gene polymorphisms on patient responses to rheumatoid arthritis therapy. Expert Opin Drug Metab Toxicol. 2015; 12(1):41-55. DOI: 10.1517/17425255.2016.1121233. View

20.

Plant D, Bowes J, Potter C, Hyrich K, Morgan A, Wilson A . Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2010; 63(3):645-53. PMC: 3084508. DOI: 10.1002/art.30130. View